#2-94E. Unmasking the Unknown: Diagnosis and Management of Idiopathic Anaphylaxis (J Allergy Clin Immunol Pract, 2025)

How do you manage a patient who returns repeatedly with life-threatening anaphylaxis, yet every allergy test comes back negative? This episode examines a 2025 Grand Rounds review on Idiopathic Anaphylaxis (IA), a diagnosis of exclusion that demands a rigorous detective approach. The authors outline a systematic workflow to differentiate IA from mimics like neuroendocrine tumors and "hidden" triggers such as alpha-gal syndrome or clonal mast cell disorders. The review’s most significant clinical implication is the emerging efficacy of the anti-IgE antibody omalizumab for patients who remain uncontrolled despite high-dose antihistamines and corticosteroids. However, we must critically appraise the strength of this recommendation, noting that the supporting evidence for such prophylactic interventions is currently limited to small case series and lacks large-scale randomized controlled trials. For physicians, this paper is an invaluable tool, providing both a concrete diagnostic algorithm and a hierarchy of therapeutic options to stabilize patients suffering from this unpredictable and often debilitating condition.

Citation: Ben-Shoshan M, Akin C, Cook VE, Khalaf R, Freigeh G. Idiopathic Anaphylaxis. J Allergy Clin Immunol Pract. 2025. DOI: 10.1016/j.jaip.2025.08.019

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.